Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

and a 56% complete response rate in a heavily pre-treated multiple myeloma population. ... Notably, Juno’s second most advanced candidate is a BCMA-targeting CAR-T - JCARH125 - which is a rival to bb2121 and is also in development for multiple myeloma.

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    abaloparatide) and confirming its earlier rejection of Pharma Mar’s Aplidin (plitidepsin) as a treatment for multiple myeloma.

  • Celgene’s triple multiple myeloma therapy clears phase III trial Celgene’s triple multiple myeloma therapy clears phase III trial

    Celgene’ s triple multiple myeloma therapy clears phase III trial. The biotech says the combo hit its OPTIMISMM primary endpoint. ... Celgene are now hoping that its new triple therapy has the potential to boost sales even further in the multiple

  • Amgen set for Kyprolis label boost after CHMP backing Amgen set for Kyprolis label boost after CHMP backing

    Amgen set for Kyprolis label boost after CHMP backing. Multiple myeloma treatment set to add new survival data. ... The Committee for Medicinal Products for Human Use (CHMP) has given the go-ahead for Amgen to add survival data to the labelling for its

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    lymphoma (DLBCL) and according to Celgene could become a $3bn product if approved in multiple blood cancer indications. ... There are some interesting wrinkles in the transaction. Juno’s second most advanced candidate is a B-cell maturation antigen

  • Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

    Johnson &Johnson’s multiple myeloma drug Darzalex has failed to win over NICE for a second time, but will be made available via the Cancer Drugs Fund (CDF) as an interim ... measure. The UK’s health technology assessment agency rejected Darzalex

More from news
Approximately 37 fully matching, plus 187 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

  • Deal Watch September 2016 Deal Watch September 2016

    Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma.

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area. ... We've got multiple region deals. So we're a flexible partner depending on what

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Focus on multiple myeloma treatment: Witnessing a transformation

    In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading. ... is a rare exception”[sic] was the opening of a recent editorial in the Lancet on multiple myeloma.

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    The latter half of the month is focused on Myeloma, as this week we head across the Atlantic to Boston, USA and  Myeloma 2016 and then back to Europe for Controversies ... in Multiple Myeloma ( CoMy) on the 28th April.This is an exciting and rewarding

  • Immuno-oncology; bringing patients closer to treatment

    Multi-stakeholder immuno-oncology experience. Blue Latitude Health has worked across a number of immunotherapies in melanoma, lung cancer, myeloma and acute lymphoblastic leukaemia. ... Immunotherapies can treat head, neck, lung, prostate, renal,

  • Blue Latitude Health

    Focus on multiple myeloma treatment: Witnessing a transformation. ... Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics